CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionReturn on equity is -786.2%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
529.88MUSDvs all stocks (USD)
Revenue (TTM)
49.59MUSDvs all stocks (USD)
Beta
0.2870xvs all stocks
52-Week Change
18.24%vs all stocks
Market Capitalization
529.88MUSDvs all stocks (USD)
Enterprise Value
433.68MUSDvs all stocks (USD)
Forward P/E
-5.20xvs Biotechnology peers
Price to Sales (TTM)
10.69xvs Biotechnology peers
Price to Book (MRQ)
6.48xvs Biotechnology peers
Enterprise to Revenue
8.75xvs Biotechnology peers
Enterprise to EBITDA
-2.55xvs Biotechnology peers
Gross Margin
83.66%vs Biotechnology peers
Operating Margin
-240.46%vs Biotechnology peers
Return on Assets (TTM)
-59.40%vs Biotechnology peers
Return on Equity (TTM)
-786.15%vs Biotechnology peers
Revenue (TTM)
49.59MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.6170USDUpdated Jul 19, 2026Quarterly Revenue Growth
6.48%vs Biotechnology peers
Gross Profit (TTM)
42.21MUSDvs all stocks (USD)
EBITDA (TTM)
-169.86MUSDvs all stocks (USD)
Net Income (TTM)
-193.96MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-150.95MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-92.68MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
30.91MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
5.30MUSDFY2025 · Dec 31, 2025Gross Profit
25.62MUSDFY2025 · Dec 31, 2025Operating Income
-170.13MUSDvs all stocks (USD)
Pre-tax Income
-209.47MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-209.47MUSDFY2025 · Dec 31, 2025EBIT
-208.33MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-178.29MUSDFY2025 · Dec 31, 2025Research & Development
114.60MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
81.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.07MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.14MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-209.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-195.06MUSDFY2025 · Dec 31, 2025Free Cash Flow
-195.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
205.23MUSDFY2025 · Dec 31, 2025Income Tax Paid
185.00KUSDFY2025 · Dec 31, 2025Interest Paid
6.36MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-209.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
728.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
6.51MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
8.42MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.83MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
-9.62MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
0.00USDFY2025 · Dec 31, 2025Long-term Debt Issuance
75.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-42.58MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
229.40MUSDFY2025 · Dec 31, 2025Shares Outstanding
87.84MSharesUpdated Jul 19, 2026Float Shares
70.38MSharesUpdated Jul 19, 2026Shares Short
24.14MSharesUpdated Jul 19, 2026Short Ratio
8.14daysvs all stocks
Short % of Shares Outstanding
27.64%vs all stocks
% Held by Insiders
0.93%vs all stocks
% Held by Institutions
98.32%vs all stocks
Total Cash (MRQ)
181.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.07USDUpdated Jul 19, 2026Total Debt (MRQ)
85.47MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.05xvs Biotechnology peers
Current Ratio (MRQ)
3.04xvs Biotechnology peers
Book Value per Share (MRQ)
0.9310USDUpdated Jul 19, 2026Total Assets
246.44MUSDvs all stocks (USD)
Total Current Assets
223.41MUSDFY2025 · Dec 31, 2025Total Liabilities
189.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
23.03MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
116.98MUSDFY2025 · Dec 31, 2025Total Current Liabilities
72.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
204.99MUSDFY2025 · Dec 31, 2025Other Short-term Investments
8.81MUSDFY2025 · Dec 31, 2025Inventory
1.83MUSDFY2025 · Dec 31, 2025Accounts Payable
12.45MUSDFY2025 · Dec 31, 2025Short-term Debt
5.84MUSDFY2025 · Dec 31, 2025Long-term Debt
81.33MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.16BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
57.20MUSDvs all stocks (USD)
52-Week Low
3.43USDUpdated Jul 19, 202652-Week High
11.25USDUpdated Jul 19, 202652-Week Change
18.24%vs all stocks
Beta
0.2870xvs all stocks
50-Day MA
4.45USDUpdated Jul 19, 2026200-Day MA
6.59USDUpdated Jul 19, 2026Avg 10-Day Volume
3.02MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.99MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.52USDUpdated Jul 19, 2026Other Income / Expense
-42.27MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -786.2%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -7.86Industry median: -0.22Industry P5: -1.66Peers compared: 261
Debt-to-equity is 1.05×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.05Industry median: 0.09Industry P95: 0.88Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
TaskUs, Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Vor Biopharma Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shenzhen Wongtee International Enterprise Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated